A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Summary

\[Phase I part\] To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, the dose to be used in the Phase II part will be confirmed. \[Phase II part\] To evaluate the efficacy of MT-2111 monotherapy in patients with relapsed/refractory DLBCL. In addition, the safety and pharmacokinetics will be investigated.

Timeline

Start

2023-01-30

Primary completion

2028-08

Completion

2028-08

Drugs

Indications